Development of a Stable MGAT1(−) CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies

The high rate of new HIV infections, particularly in Sub-Saharan Africa, emphasizes the need for a safe and effective vaccine to prevent acquired immunodeficiency syndrome (AIDS). To date, the only HIV vaccine trial that has exhibited protective efficacy in humans was the RV144 study completed in Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Doran, Rachel C., Yu, Bin, Wright, Meredith, O'Rourke, Sara M., Yin, Lu, Richardson, Jennie M., Byrne, Gabriel, Mesa, Kathryn A., Berman, Phillip W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182045/
https://www.ncbi.nlm.nih.gov/pubmed/30344523
http://dx.doi.org/10.3389/fimmu.2018.02313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182045/
https://www.ncbi.nlm.nih.gov/pubmed/30344523
http://dx.doi.org/10.3389/fimmu.2018.02313

Ejemplares similares